Source-grounded facts extracted from Mineralys Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Mineralys Therapeutics, Inc. entered into Senior Secured Term Loan Agreement with BioPharma Credit PLC valued at Up to $500,000,000 in term loans (effective 2026-06-02).
“On June 2, 2026 (the “Closing Date”), the Company entered into a senior secured term loan agreement (the “Loan Agreement”) with BioPharma Credit PLC, as collateral agent (the “Agent”), and each of BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, which are funds managed by Pharmakon Advisors, LP, as lenders.”
Shareholder Votes
Mineralys Therapeutics, Inc. shareholders approved Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-21 meeting.
“Proposal 2 — To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Abstain Broker Non-Votes 72,648,272 9,516 27,265 0”
Shareholder Votes
Mineralys Therapeutics, Inc. shareholders approved Election of three Class III directors for a three-year term expiring at the 2029 annual meeting at the 2026-05-21 meeting.
“Proposal 1 — To elect three directors to serve as Class III directors for a three-year term to expire at the 2029 annual meeting of stockholders. Name For Withhold Broker Non-Votes Srinivas Akkaraju, M.D., Ph.D. 40,667,555 26,447,538 5,569,960 Brian Taylor Slingsby, M.D., Ph.D., M.P.H. 42,487,140 24,627,953 5,569,960 Daphne Karydas 66,626,766 488,327 5,569,960”
Earnings Releases
Mineralys Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $39.3 million for the quarter ended March 31, 2026.
“On May 6, 2026, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026 and provided a corporate update.”
Earnings Releases
Mineralys Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $154.7 million.
“Net loss was $154.7 million for the year ended December 31, 2025”
Earnings Releases
Mineralys Therapeutics, Inc. reported the quarter ended December 31, 2025 results: net income $32.2 million.
“Net loss was $32.2 million for the quarter ended December 31, 2025”
Olivier Litzka resigned as Director at Mineralys Therapeutics, Inc..
“Olivier Litzka, Ph.D. informed the Board of his decision to resign from the Board, effective June 13, 2024.”
Alexander M. Gold was appointed as Class I director at Mineralys Therapeutics, Inc..
“the Board appointed Alexander M. Gold, M.D. as a member of the Board and the Nominating and Corporate Governance Committee of the Board.”
Earnings Releases
Mineralys Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $31.5 million.
“Net loss was $31.5 million for the quarter ended March 31, 2024, compared to $12.6 million for the quarter ended March 31, 2023.”
Alexander Asam departed as Director at Mineralys Therapeutics, Inc..
“On March 29, 2024, Alexander Asam, Ph.D. informed the Board of Directors (the “Board”) of Mineralys Therapeutics, Inc. (the “Company”) of his decision not to stand for re-election to the Board when his current term expires at the Company’s 2024 annual meeting of stockholders.”
Earnings Releases
Mineralys Therapeutics, Inc. reported quarter and fiscal year ended December 31, 2023 results: net income Net loss was $71.9 million for the year ended December 31, 2023, compared to $29.8 million for the year ended December 3.
“Net loss was $71.9 million for the year ended December 31, 2023, compared to $29.8 million for the year ended December 31, 2022.”
Material Agreements
Mineralys Therapeutics, Inc. entered into ATM Equity Offering Sales Agreement with BofA Securities, Inc. and Evercore Group L.L.C. valued at $100,000,000 (effective 2024-03-21).
“On March 21, 2024, Mineralys Therapeutics, Inc. (the “Company”), entered into an ATM Equity Offering Sales Agreement (the “Agreement”) with BofA Securities, Inc. and Evercore Group L.L.C. as the Company’s sales agents (the “Agents”) and/or principals. Pursuant to the terms of the Agreement, the Company may sell from time to time through the Agents shares of the Company’s common stock having an aggregate offering price of up to $100,000,000 (the “Shares”).”
Material Agreements
Mineralys Therapeutics, Inc. entered into Purchase Agreement with purchasers named therein valued at approximately $120 million (effective 2024-02-07).
“On February 7, 2024, Mineralys Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 8,339,169 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price of $13.50 per Share, and (ii) with respect to certain Purchasers, pre-funded warrants to purchase an aggregate of 549,755 shares of Common Stock (the “Pre-Funded Warrants”) in lieu of shares of Common Stock, at a purchase price of $13.499 per Pre-Funded Warrant (the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, the “Warrant Shares”). The aggregate gross proceeds for the Private Placement are expected to be approximately $120 million, before deducting offering expenses.”
Minji Kim was appointed as Chief Business Officer at Mineralys Therapeutics, Inc..
“On January 4, 2024, in connection with the appointment of Minji Kim, Ph.D., as Chief Business Officer, the Board of Directors of Mineralys Therapeutics, Inc. (the “Company”) approved splitting the functions of Chief Financial Officer and Chief Business Officer into two roles.”
Adam Levy changed role as Chief Business Officer at Mineralys Therapeutics, Inc..
“As a result, effective January 4, 2024, Adam Levy no longer serves as the Company’s Chief Business Officer.”
Earnings Releases
Mineralys Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.
“On November 7, 2023, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023 and provided a corporate update.”
Glenn P. Sblendorio was appointed as Director at Mineralys Therapeutics, Inc..
“the Board appointed Daphne Karydas and Glenn P. Sblendorio as members of the Board.”
Daphne Karydas was appointed as Director at Mineralys Therapeutics, Inc..
“the Board appointed Daphne Karydas and Glenn P. Sblendorio as members of the Board.”
Takeshi Takahashi resigned as Director at Mineralys Therapeutics, Inc..
“On September 12, 2023, Takeshi Takahashi, M.B.A., resigned from the Board of Directors (the "Board") of Mineralys Therapeutics, Inc. (the "Company").”
Earnings Releases
Mineralys Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $12.1 million for the quarter ended June 30, 2023.
“On August 7, 2023, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023”
Earnings Releases
Mineralys Therapeutics, Inc. reported first quarter 2023 results: net income $12.6 million.
“Net loss was $12.6 million for the quarter ended March 31, 2023”
Earnings Releases
Mineralys Therapeutics, Inc. reported the full-year ended December 31, 2022 results: net income $29.8 million.
“Net loss was $29.8 million for the full year ended December 31, 2022”
Governance Changes
Mineralys Therapeutics, Inc.: Amended and restated bylaws to establish procedures for stockholder proposals and director nominations, and conform to amended charter (effective 2023-02-14).
“On February 14, 2023, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Company’s board of directors to become effective upon the effectiveness of the Restated Certificate, became effective.”
Governance Changes
Mineralys Therapeutics, Inc.: Filed amended and restated certificate of incorporation upon IPO closing, increasing authorized common stock to 500M shares, authorizing 50M undesignated preferred shares, establishing a classified board, requiring cause for director removal, and eliminating stockholder action by written consent (effective 2023-02-14).
“On February 14, 2023, Mineralys Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.